Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm Metastasis × Pluvicto × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 18 Urogenital Neoplasms 1 Thrombocytopenia 1 Renal Insufficiency 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Metastatic Hormone Naive Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Liver Neoplasms 1 Kidney Neoplasms 1 Genital Neoplasms, Male 1 Cytopenia 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Hepatocellular 1 Anemia 1

Interventions

Oxaliplatin 55 Capecitabine 53 Fluorouracil 50 Bevacizumab 48 Gemcitabine 44 Leucovorin 42 Paclitaxel 39 Carboplatin 34 Nivolumab 32 Irinotecan 32 pembrolizumab 31 Docetaxel 31 Cisplatin 29 Cetuximab 29 Trastuzumab 21 Radiosurgery 20 Sunitinib 19 Cyclophosphamide 19 Panitumumab 17 Doxorubicin 17 Radiotherapy 15 Pemetrexed 15 Fulvestrant 15 Drug Therapy 15 Interleukin-2 14 Everolimus 14 atezolizumab 13 Sorafenib 13 Ipilimumab 13 Albumin-Bound Paclitaxel 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03392428 2022-06-13

TheraP

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Completed

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡